摘要
目的建立测定人血浆中去羟肌苷的液相色谱-质谱/质谱联用法(LC-MS/MS),并应用于药物制剂生物等效性评价。方法18名中国健康男性志愿者单剂量随机交叉po200 mg去羟肌苷参比制剂和受试制剂,血浆样品经沉淀蛋白处理,通过LC-MS/MS测定其浓度,采用非隔室模型计算药动学参数和相对生物利用度,并对参数进行方差分析和双单侧t检验。结果LC-MS/MS测定血浆中去羟肌苷的线性范围为5.0～2 000μg·L-1,定量下限为5.0μg·L-1。日内、日间精密度(RSD)均小于6%,准确度(RE)在±4%之内。应用本法测得18名中国健康男性志愿者po 200 mg去羟肌苷参比制剂后主要药动学参数为:tmax为(0.65±0.30)h,ρmax为(1 052±353)μg·L-1,t1/2为(1.53±0.38)h,用梯形法计算,AUC0-t为(1 628±479)μg·h·L-1,服用受试制剂后主要药动学参数为:tmax为(0.47±0.13)h,ρmax为(1 090±531)μg·L-1,t1/2为(1.44±0.46)h,AUC0-t为(1 520±661)μg·h·L-1。以AUC0-t计算相对生物利用度为(95.8±20.8)%。结论该法灵敏、快速、准确,操作简便、线性范围宽,适用于去羟肌苷制剂的生物等效性评价。
Abstract
OBJECTIVE To develop a sensitive and specific LCMS/MS method for the determination of didanosine in human plasma and to study the bioequivalence of different formulations containing didanosine.METHODS After a simple protein precipitation using acetonitrile,the samples were analyzed by liquid chromatography-tandem mass spectrometry.The pharmacokinetic parameters of didanosine in two formulations were calculated by non-compartment analysis.RESULTS The linear calibration curves were obtained in the concentration range of 5.0～2 000 μg·L-1.The intra-and inter-day relative standard deviations(RSD) over the entire concentration range were less than 6%.Accuracy(RE) determined at three concentrations was within ±4%.Pharmacokinetic parameters for the reference formulation were obtained as follows: tmax was(0.65±0.30) h,ρmax was(1 052±353) μg·L-1,t1/2 was(1.53±0.38) h,AUC0～t was(1 628±479) μg·h·L-1.Pharmacokinetic parameters for the test formulation were obtained as follows: tmax was(0.47±0.13) h,ρmax was(1 090±531) μg·L-1,t1/2 was(1.44±0.46) h ,AUC0～t was(1 520±661) μg·h·L-1.The relative bioavailability of the test formulation to the reference was(95.8±20.8)%.CONCLUSION The method is sensitive,rapid,robust,and is proved to be suitable for bioequivalence evaluation of formulations containing didanosine.
关键词
去羟肌苷 /
液相色谱-质谱-质谱联用法 /
生物等效性
{{custom_keyword}} /
Key words
didanosine /
liquid chromatography-tandem mass spectrometry /
bioequivalence
{{custom_keyword}} /
靳凤丹;陈笑艳;于河舟;安晓霞;钟大放.
血浆中去羟肌苷测定与制剂生物等效性评价[J]. 中国药学杂志, 2006, 41(13): 1016-1019
JIN Feng-dn;CHEN Xio-yn;YU He-zhou;N Xio-xi;ZHONG D-fng.
Determination of Didanosine in Human Plasma and Its Application to a Bioequivalence Study [J]. Chinese Pharmaceutical Journal, 2006, 41(13): 1016-1019
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] PERRY C M，NOBLE S. Didanosine： an updated review of its use in HIV infection[J] .Drugs，1999，58 (6)： 1099-1135.
[2] GATHE J J R，BADARO R，GRIMWOOD A，et al. Antiviral activity of enteric-coated didanosine，stavudine，and nelfinavir versus zidoovudine plus lamivudine and nelfinavir[J] .J Acquir Immune Defic Syndr，2002，31(4)： 399-403.
[3] REZK N L，TIDWELL R R，KASHUBA A D. Simultaneous determination of six HIV nucleoside analogue reverse transcriptase inhibitors and nevirapine by liquid chromatography with ultraviolet absorbance detection[J] .J Chromatogr B，2003，791(1-2)： 137-147.
[4] CAHOURS X，TRAN T T，MESPLET N，et al. Analysis of intracellular didanosine triphosphate at sub-ppb level using LC-MS/MS[J] .J Pharm Biomed Anal，2001，26(5-6)： 819-827.
[5] ESTRELA C，SALVADORI M C，RAICES R S，et al. Determination of didanosine in human serum by on-line solid-phase extraction coupled to high-performance liquid chromatography with electrospray ionization tandem mass spectrometric detection： application to a bioequivalence study[J] .J Mass Spectrom，2003，38(4)：378-385.
[6] HUANG Y，ZURLINDEN E，LIN E，et al. Liquid chromatographic-tandem mass spectrometric assay for the simultaneous determination of didanosine and stavudine in human plasma，bronchoalveolar lavage fluid，alveolar cells，peripheral blood mononuclear cells，seminal plasma，cerebrospinal fluid and tonsil tissue[J] .J Chromatogr B，2004，799(1)： 51-61.
{{custom_fnGroup.title_cn}}
脚注
{{custom_fn.content}}
